Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Gainers
Why Imugene, Mayne Pharma, Westpac, and Wildcat shares are storming higher
Share Market News
Which ASX All Ords shares have company directors been buying up?
Share Gainers
Why Evolution, Latin Resources, Mayne Pharma, and Paladin Energy shares are pushing higher
Healthcare Shares
3 ASX healthcare shares up 10% to 22% on news
Healthcare Shares
Why did this ASX All Ords share plunge 18% today?
Share Fallers
Why Austal, Chalice Mining, Fortescue, and Mayne Pharma shares are dropping today
Share Fallers
Why 4DS, Chalice Mining, Mayne Pharma, and Webjet shares are sinking today
Earnings Results
Guess which ASX 300 healthcare stock just tanked 20%
Share Market News
Returning capital: These ASX companies have been buying back their shares in 2023
Broker Notes
'Attractive valuation': 2 ASX shares QVE analysts just bought
Share Fallers
Why Appen, Bank of Queensland, Kogan, and Mayne Pharma shares are dropping
Share Gainers
Why Arafura, Core Lithium, Mayne Pharma, and Newcrest shares are storming higher
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
